PDF(Pubmed)
Abstract：
UNASSIGNED: Recent studies suggest that erythropoietin has an anti-inflammatory effect on the central nervous system. The authors aimed to investigate the effect of erythropoietin on Glasgow Coma Scale (GCS), Sequential Organ Failure Assessment (SOFA) scores, and the mortality rate of traumatic brain injury (TBI) patients.
UNASSIGNED: Sixty-eight patients with available inclusion criteria were randomly allocated to the control or intervention groups. In the intervention group, erythropoietin (4000 units) was administrated on days 1, 3, and 5. In the control group, normal saline on the same days was used. The primary outcomes were the GCS and SOFA score changes during the intervention. The secondary outcomes were the ventilation period during the first 2 weeks and the 3-month mortality rate.
UNASSIGNED: Erythropoietin administration significantly affected SOFA score over time (P=0.008), but no significant effect on the GCS, and duration of ventilation between the two groups was observed. Finally, erythropoietin had no significant effect on the three-month mortality (23.5% vs. 38.2% in the erythropoietin and control group, respectively). However, the mortality rate in the intervention group was lower than in the control group.
UNASSIGNED: Our finding showed that erythropoietin administration in TBI may improve SOFA score. Therefore, erythropoietin may have beneficial effects on early morbidity and clinical improvement in TBI patients.
UNASSIGNED: Sixty-eight patients with available inclusion criteria were randomly allocated to the control or intervention groups. In the intervention group, erythropoietin (4000 units) was administrated on days 1, 3, and 5. In the control group, normal saline on the same days was used. The primary outcomes were the GCS and SOFA score changes during the intervention. The secondary outcomes were the ventilation period during the first 2 weeks and the 3-month mortality rate.
UNASSIGNED: Erythropoietin administration significantly affected SOFA score over time (P=0.008), but no significant effect on the GCS, and duration of ventilation between the two groups was observed. Finally, erythropoietin had no significant effect on the three-month mortality (23.5% vs. 38.2% in the erythropoietin and control group, respectively). However, the mortality rate in the intervention group was lower than in the control group.
UNASSIGNED: Our finding showed that erythropoietin administration in TBI may improve SOFA score. Therefore, erythropoietin may have beneficial effects on early morbidity and clinical improvement in TBI patients.
摘要：
■最近的研究表明促红细胞生成素对中枢神经系统具有抗炎作用。作者旨在研究促红细胞生成素对格拉斯哥昏迷量表（GCS）的影响。序贯器官衰竭评估（SOFA）评分，以及创伤性脑损伤（TBI）患者的死亡率。
■68例符合纳入标准的患者被随机分配到对照组或干预组。在干预组中，在第1、3和5天施用促红细胞生成素(4000单位)。在对照组中，同日使用生理盐水。主要结果是干预期间GCS和SOFA评分的变化。次要结果是前2周的通气期和3个月的死亡率。
■促红细胞生成素给药随着时间的推移显著影响SOFA评分（P=0.008），但对GCS没有显著影响,观察两组患者的通气时间。最后,促红细胞生成素对三个月死亡率没有显著影响(23.5%vs.促红细胞生成素和对照组为38.2%，分别)。然而,干预组的死亡率低于对照组。
■我们的发现表明，在TBI中使用促红细胞生成素可以改善SOFA评分。因此,促红细胞生成素可能对TBI患者的早期发病和临床改善有有益作用。
■68例符合纳入标准的患者被随机分配到对照组或干预组。在干预组中，在第1、3和5天施用促红细胞生成素(4000单位)。在对照组中，同日使用生理盐水。主要结果是干预期间GCS和SOFA评分的变化。次要结果是前2周的通气期和3个月的死亡率。
■促红细胞生成素给药随着时间的推移显著影响SOFA评分（P=0.008），但对GCS没有显著影响,观察两组患者的通气时间。最后,促红细胞生成素对三个月死亡率没有显著影响(23.5%vs.促红细胞生成素和对照组为38.2%，分别)。然而,干预组的死亡率低于对照组。
■我们的发现表明，在TBI中使用促红细胞生成素可以改善SOFA评分。因此,促红细胞生成素可能对TBI患者的早期发病和临床改善有有益作用。
